Complimentary access to the JTO and a 15% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 21.1, JTO is among the top 4% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews, and opinion pieces. JTO CRR, IASLC’s open-access companion title, publishes a range of manuscripts, from subset analyses of published trials to high-quality case reports. JTO CRR has an Impact Factor of 3.0 and is indexed in PubMed and Web of Science.
JTO by the Numbers
EDITOR-IN-CHIEF, JTO ON 2024 IMPACT FACTOR
Alex A. Adjei, MD, PhD, FACP
"I would like to share the Journal of Thoracic Oncology's (JTO) progress with you. The Impact Factor is 20.8. This is a slight decrease from 21.1 last year. The journal remains a "high impact journal" with an IF > 20. The journal ranks third among 108 respiratory medicine journals and remains at 13th among 326 oncology journals. Because of the narrower focus, it is generally difficult for organ specific oncology journals to make a significant impact in the oncology publishing landscape. With an Impact Factor of 20.8, JTO is the leading journal in thoracic oncology and in the top thirteen of all three hundred and twenty-six cancer journals.
As the leading thoracic oncology journal, its strength is in its multidisciplinary approach to research. JTO continues to have a quick turn-around time of one week to initial decision, and an average of 2.8 weeks for revisions, a fast-track category, publish on acceptance, and promotion of select articles via social media and press releases. Authors can promote their own research by utilizing Elsevier enhancements such as Sharelink.
The continued prominence of JTO in the highly competitive general oncology journal landscape is due to the support of the IASLC office and IASLC members, as well as our dedicated publishing team and exceptional editorial board members."
JTO CRR By the Numbers
EDITOR-IN-CHIEF, JTO CRR ON 2024 IMPACT FACTOR
Emily Stone, MBBS, PhD, FRACP
"I am delighted to share with you that the impact factor for JTO Clinical and Research Reports (JTO CRR) is 3.5, an increase from last year's IF of 3.0. This puts the journal in the top half of oncology journals and in the top third of respiratory journals. This reflects the tremendous support from the IASLC, the journal team as a whole, the remarkable group of Associate Editors, our editorial office team, and all our reviewers.
As you know, an academic journal's impact factor reflects the frequency of citations for an average article in a particular year and is used as a marker for rank, importance, and prestige.
JTO CRR, the open-access sister journal to JTO, provides researchers with opportunities to publish a wide range of studies in thoracic oncology and is committed to the very highest quality research. We work hard on rapid turn-around with time to first decision of less than one week, prompt review, and publication on acceptance via the Article-Based Publishing workflow at Elsevier.
I would like to thank our submitting authors, reviewers, editorial board members, editorial and publication staff, and, of course, the IALSC for supporting this journal. JTO CRR looks set for an exciting future."
Most-Cited Journal of Thoracic Oncology Articles in 2024
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer
Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Recent journal articles
Surgical Outcomes with Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
Brief Report: First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients from East 3 Asia with RET Fusion-positive NSCLC: A LIBRETTO-431 Subgroup Analysis
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis
BRAF fusion as resistance mechanism to osimertinib in EGFR-mutated NSCLC: a case report and review of literature
Impact of the COVID-19 pandemic on diagnosis and multidisciplinary treatment of NSCLC in Ontario, Canada
Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-mutant lung cancer
Midkine expression as a candidate biomarker to predict the recurrence of stage IA lung adenocarcinoma
CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC
Discover the JTO
JTO.org offers numerous ways to stay abreast of novel research and information vital to your daily oncology practice. Join the JTO reader community to:
More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 1 week to initial decision, and an average of 1.6 weeks for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.
JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.
JTO reviewers are given the privilege of getting the first look at novel research, phase III data, and potentially practice-changing concepts. Email your CV to JTO@iaslc.org.
New JTO Collections
Discover the JTO CRR
Providing a more clinical focus, the JTO CRR contains phase I thoracic oncology clinical trials and single-arm phase II trials, as well as case reports, subset analyses of a published trials, database analyses, retrospective trials, and large single-institution series.
In addition to the content discussed previously, JTO CRR also accepts region-specific clinical trials, subspecialty thoracic oncology studies, and select high-quality meeting reports.
To become a JTO CRR Reviewer email your CV to JTOCRR@iaslc.org.
Related Content
